Adverse cardiac remodeling after acute myocardial infarction (MI), regardless of primary percutaneous coronary intervention, is strongly associated with the development of heart failure and poor prognosis. Since demographic and clinical characteristics are not sufficiently sensitive to predict adverse remodeling after MI, more precise parameters are needed to identify individuals at risk of progression to ventricular dysfunction and heart failure, potentially allowing an early and intensive prognosis modifying therapy. New biomarkers of adverse cardiac remodeling have emerged, such as matrix metalloproteinases […]